

Infectious challenges of urology

Poster Session 06

Friday, 24 March
12:30 - 14:00

Location: Room Milan, North Hall (Level 1)

Chairs: R. Bartoletti, Pisa (IT)
B. Köves, Budapest (HU)
P. Tenke, Budapest (HU)

Aims and objectives of this session

This session presents the latest information for the care of your patients.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- 75 **Morbidity and mortality outcomes in urosepsis compared according to new sepsis definitions: A prospective multinational observational study – systemic inflammatory response syndrome protects its value**
By: [Tandoi du Z.](#)¹, Koves B.², Cai T.³, Platz A.⁴, Wagenlehner F.⁴, Bjerklund Johansen T.E.⁵
Institutes:¹Oslo University, Institute of Clinical Medicine, Oslo, Norway, ²South Pest Teaching Hospital, Dept. of Urology, Budapest, Hungary, ³Santa Chiara Hospital, Dept. of Urology, Trento, Italy, ⁴Universitätsklinikum Gießen und Marburg GmbH, Pediatric Urology and Andrology, Giessen, Germany, ⁵Oslo University, Dept. of Urology and Institute of Clinical Medicine, Oslo, Norway
- 76 **Risk factors for mortality in patients with urosepsis**
By: [Fukunaga A.](#), Kawakita M.
Institutes:Kobe City Medical Center General Hospital, Dept. of Urology, Kobe, Japan
- 78 **A novel predictive tool for Asian Fournier's gangrene: 40 cases and 15-year-experience of a tertiary center**
By: [Lin Y-H.](#)¹, Lu Y-C.², Hong J-H.², Liao C-H.¹, Huang K-H.², Huang C-Y.², Liu S-P.², Pu Y-S.²
Institutes:¹Cardinal Tien Hospital, Division of Urology, Dept. of Surgery, New Taipei City, Taiwan, ²National Taiwan University Hospital, Dept. of Urology, Taipei, Taiwan
- 79 **Identification of distant subcutaneous spreading of Fournier's gangrene by intraoperative ultrasound**
By: [Cantoro D.](#)¹, Galosi A.B.¹, Maselli G.¹, Sbrollini G.¹, Fulvi P.¹, Dell'Atti L.²
Institutes:¹Università Politecnica Delle Marche - Ospedali Riuniti di Ancona, Dept. of Urology, Ancona, Italy, ²Ospedale S. Anna, Dept. of Urology, Ferrara, Italy
- 80 **Five-year prospective study evaluating healthcare-associated infections (HAIs) in a urology ward: Risk factors, microbiological characteristics and resistance patterns**
By: [Medina Polo J.](#), Sopeña-Sutil R., Benítez-Sala R., Lara-Isa A., Alonso-Isa M., Gil-Moradillo J., Justo-Quintas J., García-Rojo E., González-Padilla D.A., González-Díaz A., Abad-López P., Passas-Martínez J.B., Tejido-Sánchez A.
Institutes:Hospital Universitario 12 de Octubre, Dept. of Urology, Madrid, Spain
- 81 **Quick SOFA score might be inadequate as initial sepsis screening system in UTI patients**
By: [Fujita S.](#), Naito S., Ichiyanagi O., Kanno H., Yamagishi A., Yagi M., Kurota Y., Sakurai T., Nishida H., Shibasaki T., Kawazoe H., Kato T., Nagaoka A., Tsuchiya N.
Institutes:Yamagata University, School of Medicine, Dept. of Urology, Yamagata City, Japan
- 82 **Detecting bacterial resistance in urine at the point of care via a custom tailored LAMP panel**
By:

Fritzenwanker M.¹, Imirzalioglu C.¹, Wagenlehner F.², Chakraborty T.¹, Schwengers O.³, Blom J.³
Institutes:¹Justus-Liebig-Universität, Institut Für Medizinische Mikrobiologie, Giessen, Germany,
²Justus-Liebig-Universität, Klinik Für Urologie, Kinderurologie Und Andrologie, Giessen, Germany,
³Justus-Liebig-Universität, Dept. of Bioinformatics and Systems Biology, Giessen, Germany

83 **Establishment of a 3D organotypic urothelial cell culture model as infection model system for BK polyomavirus – viral lifecycle and identification of new therapeutic targets**

By: Schneidewind L.¹, Knerr-Rupp K.¹, Feld P.¹, Janssen M.², Keiser M.³, Smola S.¹

Institutes:¹University of The Saarland Medical Center, University of The Saarland, Dept. of Virology, Homburg, Germany, ²University of The Saarland Medical Center, University of The Saarland, Dept. of Urology and Paediatric Urology, Homburg, Germany, ³University Medicine Greifswald, Dept. of Pharmacology, Greifswald, Germany

84 **Antimicrobial resistance patterns and risk factors for ciprofloxacin in Enterococcus faecalis isolates from expressed prostatic secretions of patients with chronic bacterial prostatitis**

By: Lee G.¹, Seo Y.¹, Song J.²

Institutes:¹Dankook University Medical College, Dept. of Urology, Cheonan, South Korea, ²Yonsei University Wonju College of Medicine, Dept. of Urology, Wonju, South Korea

85 **Withdrawn**

By:

Institutes:

86 **Prostatic secretion microbiota and chronic bacterial prostatitis symptoms or signs: Is there a connection?**

By: Kogan M.L.¹, Naboka J.², Gudima I.², Ibishev H.¹

Institutes:¹Rostov State Medical University, Dept. of Urology, Rostov-on-Don, Russia, ²Rostov State Medical University, Dept. of Microbiology, Rostov-on-Don, Russia

87 **Does micropattern (sharklet) on urinary catheter surface reduce urinary tract infections? Results from phase I randomized open label interventional trial**

By: Magyar A.¹, Arthanareeswaran V.K.A.¹, Soós L.¹, Nagy K.¹, Dobák A.², Szilágyi I.M.³, Justh N.³, Chandra A.R.¹, Köves B.¹, Tenke P.¹

Institutes:¹Jahn Ferenc Dél-pesti Kórház, Dept. of Urology, Budapest, Hungary, ²Corden International, Dept. of Microbiology, Budapest, Hungary, ³University of Technology and Economics, BME, Budapest, Hungary

88 **How to overcome gram-positive bacterial identification in matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for complicated urinary tract infection-causative bacteria?**

By: Shigemura K.¹, Kitagawa K.², Yamamichi F.³, Nakano Y.¹, Tokimatsu I.⁴, Fujisawa M.¹

Institutes:¹Kobe University Graduate School of Medicine, Dept. of Urology, Kobe, Japan, ²Kobe University Graduate School of Medicine, Dept. of Internal Related, Kobe, Japan, ³Hyogo Prefectural Amagasaki General Medical Center, Dept. of Urology, Amagasaki, Japan, ⁴Kobe University Hospital, Infection Control Team, Kobe, Japan

89 **The adherence to European Association of Urology guidelines on urological infection in a tertiary referral hospital is the right way for increasing the antimicrobial stewardship among general practitioners**

By: Cai T.¹, Mazzoli S.², Verze P.³, Migno S.⁴, Tiscione D.¹, Luciani L.¹, Lanzafame P.⁵, Eccher C.¹, Malossini G.¹, Bartoletti R.⁶, Mirone V.³, Wagenlehner F.⁷, Bjerklund Johansen T.⁸

Institutes:¹Santa Chiara Hospital, Dept. of Urology, Trento, Italy, ²Santa Maria Annunziata Hospital, Sexually Transmitted Disease Centre, Florence, Italy, ³University of Naples, Federico II, Dept. of Urology, Naples, Italy, ⁴Santa Chiara Hospital, Dept. of Gynaecology and Obstetrics, Trento, Italy, ⁵Santa Chiara Hospital, Department of Microbiology, Trento, Italy, ⁶University of Pisa, Dept. of Urology, Pisa, Italy, ⁷Universitätsklinikum Giessen und Marburg GmbH, Justus-Liebig-Universität, Klinik und Poliklinik für Urologie, Kinderurologie und Andrologie, Giessen, Germany, ⁸University of

Oslo, Dept. of Urology, Oslo, Norway